Medicure Inc.

198 articles with Medicure Inc.

• Medicure reports financial results for quarter ended September 30, 2018

  11/20/2018

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2018. 

• Medicure Files Patent Infringement Action

  11/16/2018

  Medicure Inc. today announces that its subsidiary, Medicure International Inc., has filed a patent infringement action against Gland Pharma Ltd. ("Gland") in the U.S. District Court for the District of New Jersey, alleging infringement of U.S. Patent No. 6,770,660 ("the '660 patent").

• Medicure Q3 2018 Results and Conference Call Dates

  11/14/2018

   Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2018 on Tuesday, November 20, 2018.

• Medicure Reports Financial Results for Quarter Ended June 30, 2018

  8/15/2018

  Medicure Inc. reported its results from operations for the quarter ended June 30, 2018.

• Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection

  8/13/2018

  Medicure Inc.. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that the Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application ("ANDA") for Sodium Nitroprusside Injection 50 mg/2 mL (25 mg/mL) single dose vial ("SNP"), a generic intravenous cardiovascular drug product.

• Medicure Q1 2018 Results and Conference Call Dates

  5/17/2018

  Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the first quarter ended March 31, 2018 on Wednesday, May 23, 2018.

• Medicure Reports Financial Results for Quarter and Year Ended December 31, 2017

  5/2/2018

  Medicure Inc. reported its results from operations for the quarter and year ended December 31, 2017.

• Medicure announces availability of ZYPITAMAG (pitavastatin) in the U.S.

  5/1/2018

  Medicure announced that pitavastatin magnesium (ZYPITAMAGTM) tablets are now available in retail pharmacies throughout the United States.

• Medicure Announces Further Up-Date on PREXXARTAN®

  3/28/2018

  Medicure continues to reserve all of its rights under the license agreement with Carmel for PREXXARTAN®.

• Medicure Announces an Up-Date on PREXXARTAN Launch

  3/19/2018

  Medicure had intended to launch PREXXARTAN® during the first half of 2018.

• Medicure Announces Receipt of Deferred Proceeds from Apicore Sale

  2/1/2018

  Medicure today announced that it has received the deferred purchase price proceeds of approximately US$50 million from the sale of its interests in Apicore to an arm's length, pharmaceutical company (the "Buyer"), a transaction that closed and was announced in October 2017.

• Medicure Announces FDA Approval Received for Prexxartan

  12/20/2017

  The FDA approval of Prexxartan makes it the first and only approved oral liquid dosage form of the ARB valsartan in the United States.

• Medicure Acquires Exclusive License to Sell and Market Branded Cardiovascular Drug in the U.S.

  12/14/2017

  The licensing agreement is for a term of seven years with extensions to the term available.

• Medicure Reports Financial Results for Quarter Ended September 30, 2017

  11/22/2017

  Recorded net revenue from the sale of AGGRASTAT of $7M during the quarter ended September 30, 2017 compared to $8.2M for the quarter ended September 30, 2016.

• Medicure Announces Repayment of Outstanding Debt

  11/20/2017

  Medicure today announced that it has repaid in full its loans with the MDC and Crown Capital Fund IV, LP, an investment fund managed by Crown.

• Medicure Q3 Results and Conference Call Dates

  11/16/2017

  Medicure will hold a conference call and webcast regarding the results on Wednesday, November 22, 2017 at 7:30 AM Central Time.

• Medicure Acquires License to Sell and Market PREXXARTAN in the U.S. From Carmel Biosciences

  11/1/2017

  Under terms of the agreement, Medicure obtains exclusive rights in the United States and territories to develop, manufacture and market PREXXARTAN for a seven year term, with potential extensions to the term available.

• Medicure Acquires Exclusive License to Sell and Market PREXXARTAN in the U.S. From Carmel Biosciences

  11/1/2017

  Medicure has acquired an exclusive license to sell and market PREXXARTAN (valsartan) oral solution in the U.S. and its territories from Carme for a seven year term with extensions to the term available.

• Medicure Announces Sale Of Apicore Business

  10/3/2017

• Medicure Reports Financial Results For Quarter Ended June 30, 2017

  8/8/2017